Monday, January 29, 2024 3:04:17 PM
I feel the same way at ten cents. I think on positive results we could see .40 cents for starters. The Question is will the stock get bought up further in anticipation of FDA approval in June? Either way these prices are insane. I really believe the shorts are counting on another reverse split and are hoping that it goes lower. I think this time we are too close and this will go up from here.
Bullish
Recent JAGX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 01:57:16 PM
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs • ACCESS Newswire • 04/29/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 01:10:06 PM
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split • ACCESS Newswire • 04/27/2026 01:00:00 PM
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) • ACCESS Newswire • 04/24/2026 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/21/2026 12:22:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:35:12 AM
- Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders • ACCESS Newswire • 04/20/2026 08:15:00 PM
- Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs • ACCESS Newswire • 04/13/2026 12:30:00 PM
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates • ACCESS Newswire • 04/10/2026 12:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:04:50 PM
- Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs • ACCESS Newswire • 04/08/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/07/2026 09:08:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:22 PM
- Jaguar Health Reports 2025 Financials • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/07/2026 10:10:28 AM
- Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress • ACCESS Newswire • 04/02/2026 01:00:00 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:19:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/24/2026 09:06:18 PM
- FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 03/18/2026 01:00:00 PM
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression • ACCESS Newswire • 03/16/2026 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/13/2026 08:59:50 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts • ACCESS Newswire • 03/11/2026 01:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM

